Compare Sanofi SA (SNY) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Sprott Uranium Miners ETF — how do they compare? Sanofi SA trades at $42.96 (market cap $103.41B), while Sprott Uranium Miners ETF trades at $56.07. The key difference: Sanofi SA pays a 5.65% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals.
| SNY | URNM | |
|---|---|---|
Market Cap | $103.41B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $52.34 | $83.99 |
52-Week Low | $41.33 | $47.13 |
Enterprise Value | $123.44B | — |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
URNM, a uranium-focused ETF, trades at $57.38, up 0.54% today, with neutral technical signals and bearish moving averages. Key support lies at $55, resistance at $58. The fund provides concentrated exposure to uranium miners, benefiting from long-term supply deficits and rising AI-driven power demand, though financial ratios are not disclosed for the ETF structure.
Outlook is cautiously optimistic due to nuclear energy's role in AI infrastructure and government funding, but risks include uranium price volatility and miner concentration. Analyst sentiment is mixed, with some bullish on supply crunches while others warn of overvaluation in miner equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
